Key Results (Week 26 interim data): Semaglutide alone: 35% of weight lost was lean mass (muscle) Combo w/ trevogrumab (anti-myostatin): Preserved ~50% lean mass loss
Available data suggest oral semaglutide trends higher for nausea, vomiting, dyspepsia, and headache, while Foundayo trends higher for diarrhoea, constipation, abdominal pain, and fatigue
Avoid Semaglutide if you have: History of medullary thyroid cancer
PlexusDx compounded semaglutide injections available from licensed 503A pharmacies ensure consistent, high-quality medication that supports this gradual adaptation process
This resistance has been linked to chronic health conditions such as heart disease, fatty liver disease, and cognitive decline
helping you avoid side effects and achieve meaningful, measurable progress